Allogene Therapeutics is a biotechnology company developing allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors.
Cell Medica develops therapeutics based on cellular immunotherapy with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant.
Legend Biotech's first product candidate, LCAR-B38M, is a B cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy. The novel dual-epitope design of the BCMA ...
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products ...
The backbone of the ARCUS technology is the ARC Nuclease – a fully synthetic enzyme that is very similar to a homing endonuclease but is modified to be a better starting point for the development ...
